HeartWare Presents New VAD Data; Thrombus Rates Prompt Concerns
This article was originally published in The Gray Sheet
Executive SummaryHeartWare presented longer-term data from its bridge-to-transplant ADVANCE trial for its left ventricular assist device earlier this month. The data largely mirrored results presented last year, but newly increased thrombus rates prompted questions.
You may also be interested in...
Thoratec’s virtual monopoly in the LVAD market is about to end with the anticipated launch of HeartWare’s system this month or next, but executives are not displaying major concern.